0	14	Interleukin-10	Interleukin-10	NNP
15	25	stabilizes	stabilize	VBZ
26	36	inhibitory	inhibitory	JJ
37	49	kappaB-alpha	kappab-alpha	NN
50	52	in	in	IN
53	58	human	human	JJ
59	68	monocytes	monocyte	NNS
68	69	.	.	.

71	85	Interleukin-10	Interleukin-10	NNP
86	87	(	(	(
87	92	IL-10	IL-10	NNP
92	93	)	)	)
94	102	protects	protect	VBZ
103	110	animals	animal	NNS
111	115	from	from	IN
116	122	lethal	lethal	JJ
123	134	endotoxemia	endotoxemia	NN
134	135	.	.	.

136	140	This	this	DT
141	151	beneficial	beneficial	JJ
152	158	effect	effect	NN
159	161	is	be	VBZ
162	170	mediated	mediate	VBN
170	171	,	,	,
172	174	in	in	IN
175	179	part	part	NN
179	180	,	,	,
181	183	by	by	IN
184	194	inhibition	inhibition	NN
195	197	of	of	IN
198	210	inflammatory	inflammatory	JJ
211	219	cytokine	cytokine	NN
220	230	production	production	NN
230	231	,	,	,
232	241	including	include	VBG
242	247	tumor	tumor	NN
248	256	necrosis	necrosis	NN
257	269	factor-alpha	factor-alpha	NN
270	271	(	(	(
271	280	TNF-alpha	TNF-alpha	NNP
280	281	)	)	)
281	282	.	.	.

283	291	Evidence	evidence	NN
292	300	suggests	suggest	VBZ
301	305	that	that	IN
306	311	IL-10	il-10	NN
312	315	may	may	MD
316	323	inhibit	inhibit	VB
324	334	activation	activation	NN
335	337	of	of	IN
338	341	the	the	DT
342	355	transcription	transcription	NN
356	362	factor	factor	NN
363	370	nuclear	nuclear	JJ
371	384	factor-kappaB	factor-kappaB	NNP
385	386	(	(	(
386	395	NF-kappaB	NF-kappaB	NNP
395	396	)	)	)
397	404	through	through	IN
405	407	an	an	DT
408	415	unknown	unknown	JJ
416	425	mechanism	mechanism	NN
425	426	.	.	.

427	436	NF-kappaB	NF-kappaB	NNP
437	447	activation	activation	NN
448	450	in	in	IN
451	459	response	response	NN
460	462	to	to	TO
463	475	inflammatory	inflammatory	JJ
476	483	signals	signal	NNS
484	486	is	be	VBZ
487	496	dependent	dependent	JJ
497	501	upon	upon	IN
502	513	degradation	degradation	NN
514	516	of	of	IN
517	520	its	its	PRP$
521	531	associated	associate	VBN
532	542	inhibitory	inhibitory	JJ
543	550	peptide	peptide	NN
550	551	,	,	,
552	562	inhibitory	inhibitory	JJ
563	575	kappaB-alpha	kappab-alpha	NN
576	577	(	(	(
577	590	IkappaB-alpha	IkappaB-alpha	NNP
590	591	)	)	)
591	592	.	.	.

593	595	We	we	PRP
596	608	hypothesized	hypothesize	VBD
609	613	that	that	IN
614	619	IL-10	IL-10	NNP
620	628	prevents	prevent	VBZ
629	634	human	human	JJ
635	643	monocyte	monocyte	NN
644	653	NF-kappaB	nf-kappab	NN
654	664	activation	activation	NN
665	668	and	and	CC
669	678	resultant	resultant	JJ
679	688	TNF-alpha	TNF-alpha	NNP
689	699	production	production	NN
700	702	by	by	IN
703	716	stabilization	stabilization	NN
717	719	of	of	IN
720	733	IkappaB-alpha	IkappaB-alpha	NNP
733	734	.	.	.

735	738	The	the	DT
739	746	purpose	purpose	NN
747	749	of	of	IN
750	754	this	this	DT
755	760	study	study	NN
761	764	was	be	VBD
765	767	to	to	TO
768	777	determine	determine	VB
778	781	the	the	DT
782	788	effect	effect	NN
789	791	of	of	IN
792	797	IL-10	il-10	NN
798	800	on	on	IN
801	819	lipopolysaccharide	lipopolysaccharide	NN
820	821	(	(	(
821	833	LPS)-induced	lps)-induced	JJ
834	839	human	human	JJ
840	848	monocyte	monocyte	NN
849	858	TNF-alpha	TNF-alpha	NNP
859	869	production	production	NN
869	870	,	,	,
871	880	NF-kappaB	NF-kappaB	NNP
881	891	activation	activation	NN
891	892	,	,	,
893	896	and	and	CC
897	910	IkappaB-alpha	IkappaB-alpha	NNP
911	922	degradation	degradation	NN
922	923	.	.	.

924	933	Monocytes	Monocyte	NNP
934	938	were	be	VBD
939	947	isolated	isolate	VBN
948	952	from	from	IN
953	958	human	human	JJ
959	965	donors	donor	NNS
965	966	.	.	.

967	972	Cells	cell	NNS
973	977	were	be	VBD
978	988	stimulated	stimulate	VBN
989	993	with	with	IN
994	1003	endotoxin	endotoxin	NN
1004	1005	(	(	(
1005	1008	LPS	LPS	NNP
1008	1009	,	,	,
1010	1013	100	100	CD
1014	1019	ng/mL	ng/ml	NN
1019	1020	)	)	)
1021	1025	with	with	IN
1026	1029	and	and	CC
1030	1037	without	without	IN
1038	1043	human	human	JJ
1044	1049	IL-10	il-10	NN
1050	1051	(	(	(
1051	1053	10	10	CD
1054	1059	ng/mL	ng/ml	NN
1059	1060	)	)	)
1060	1061	.	.	.

1062	1071	Following	follow	VBG
1072	1083	stimulation	stimulation	NN
1083	1084	,	,	,
1085	1094	TNF-alpha	TNF-alpha	NNP
1095	1098	was	be	VBD
1099	1107	measured	measure	VBN
1108	1110	in	in	IN
1111	1115	cell	cell	NN
1116	1128	supernatants	supernatant	NNS
1129	1131	by	by	IN
1132	1137	ELISA	ELISA	NNP
1137	1138	,	,	,
1139	1148	NF-kappaB	NF-kappaB	NNP
1149	1157	activity	activity	NN
1158	1160	by	by	IN
1161	1176	electrophoretic	electrophoretic	JJ
1177	1185	mobility	mobility	NN
1186	1191	shift	shift	NN
1192	1197	assay	assay	NN
1197	1198	,	,	,
1199	1202	and	and	CC
1203	1216	IkappaB-alpha	IkappaB-alpha	NNP
1217	1223	levels	level	NNS
1224	1226	by	by	IN
1227	1234	Western	western	JJ
1235	1239	blot	blot	NN
1239	1240	.	.	.

1241	1243	We	we	PRP
1244	1252	observed	observe	VBD
1253	1257	that	that	IN
1258	1263	after	after	IN
1264	1267	LPS	LPS	NNP
1268	1279	stimulation	stimulation	NN
1280	1282	of	of	IN
1283	1288	human	human	JJ
1289	1298	monocytes	monocyte	NNS
1298	1299	,	,	,
1300	1309	TNF-alpha	TNF-alpha	NNP
1310	1319	increased	increase	VBD
1320	1322	to	to	TO
1323	1331	798+/-67	798+/-67	CD
1332	1337	pg/mL	pg/ml	NN
1338	1339	(	(	(
1339	1340	p	p	NN
1341	1342	<	<	JJR
1343	1347	.001	.001	CD
1348	1354	versus	versus	CC
1355	1362	control	control	NN
1362	1363	)	)	)
1363	1364	.	.	.

1365	1370	IL-10	IL-10	NNP
1371	1381	attenuated	attenuate	VBD
1382	1396	LPS-stimulated	lps-stimulated	JJ
1397	1406	TNF-alpha	TNF-alpha	NNP
1407	1417	production	production	NN
1418	1419	(	(	(
1419	1427	297+/-54	297+/-54	CD
1427	1428	;	;	:
1429	1430	p	p	NN
1431	1432	<	<	JJR
1433	1437	.001	.001	CD
1438	1444	versus	versus	CC
1445	1448	LPS	lps	NN
1449	1454	alone	alone	RB
1454	1455	)	)	)
1455	1456	.	.	.

1457	1462	After	after	IN
1463	1466	LPS	LPS	NNP
1467	1478	stimulation	stimulation	NN
1479	1481	in	in	IN
1482	1487	human	human	JJ
1488	1497	monocytes	monocyte	NNS
1497	1498	,	,	,
1499	1512	IkappaB-alpha	IkappaB-alpha	NNP
1513	1520	protein	protein	NN
1521	1527	levels	level	NNS
1528	1537	decreased	decrease	VBD
1537	1538	,	,	,
1539	1542	and	and	CC
1543	1552	NF-kappaB	NF-kappaB	NNP
1553	1556	DNA	DNA	NNP
1557	1564	binding	binding	NN
1565	1574	increased	increase	VBD
1574	1575	.	.	.

1576	1581	IL-10	IL-10	NNP
1582	1594	pretreatment	pretreatment	NN
1595	1604	prevented	prevent	VBD
1605	1616	LPS-induced	lps-induced	JJ
1617	1626	decreases	decrease	NNS
1627	1629	in	in	IN
1630	1643	IkappaB-alpha	IkappaB-alpha	NNP
1644	1651	protein	protein	NN
1652	1658	levels	level	NNS
1659	1662	and	and	CC
1663	1673	attenuated	attenuate	VBD
1674	1683	NF-kappaB	NF-kappaB	NNP
1684	1687	DNA	DNA	NNP
1688	1695	binding	binding	NN
1695	1696	.	.	.

1697	1702	IL-10	IL-10	NNP
1703	1710	appears	appear	VBZ
1711	1713	to	to	TO
1714	1721	prevent	prevent	VB
1722	1732	activation	activation	NN
1733	1735	of	of	IN
1736	1745	NF-kappaB	NF-kappaB	NNP
1746	1748	by	by	IN
1749	1759	preserving	preserve	VBG
1760	1773	IkappaB-alpha	IkappaB-alpha	NNP
1774	1781	protein	protein	NN
1782	1788	levels	level	NNS
1788	1789	,	,	,
1790	1797	leading	lead	VBG
1798	1800	to	to	TO
1801	1802	a	a	DT
1803	1812	reduction	reduction	NN
1813	1815	in	in	IN
1816	1825	TNF-alpha	TNF-alpha	NNP
1826	1833	release	release	NN
1833	1834	.	.	.